Opportunities and Risks of a Single-Trial Default for FDA Drug Approval

Q: What does this research mean for the field?

A single-trial default for FDA drug approval presents specific potential concerns and opportunities for the regulatory process. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Reshma Ramachandran; Rachel E. Sachs; Patricia J. Zettler; Holly Fernandez Lynch

doi:10.1001/jamahealthforum.2026.2756

September 4, 2026JAMA Health ForumOpen Access

Opportunities and Risks of a Single-Trial Default for FDA Drug Approval

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the clinical, regulatory, and safety implications of adopting a single pivotal clinical trial as the default evidentiary standard for FDA drug approval.
Expert viewpoint and policy analysis assessing US Food and Drug Administration evidentiary frameworks.
Evaluation of regulatory tradeoffs between accelerated development timelines and clinical certainty.
Identifies faster patient access to novel therapies and reduced development costs as primary advantages of a single-trial framework.
Highlights major risks including elevated rates of false-positive efficacy findings and uncharacterized safety profiles.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Policy review reveals tradeoffs of single-trial defaults in drug development, highlighting potential compromises between accelerated market access and evidentiary certainty.

Abstract

This Viewpoint describes potential concerns and opportunities with a single-trial default for US Food and Drug Administration (FDA) drug approval.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ramachandran et al. (2026) studied this question.

synapsesocial.com/papers/6a9d1e7228139818eab213d8 https://doi.org/10.1001/jamahealthforum.2026.2756

View Full Paper

Ask AI

Bookmark

Share

Opportunities and Risks of a Single-Trial Default for FDA Drug Approval

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Opportunities and Risks of a Single-Trial Default for FDA Drug Approval

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading